Monitoring progress with regular check-ins and adjustments
It comes in three FDA-approved forms: Ozempic: weekly injection for type 2 diabetes (0.25 to 2.0 mg) Wegovy: weekly injection for obesity (0.25 to 2.4 mg), plus an oral tablet approved December 2025 (50 mg daily) Rybelsus: daily oral tablet for T2D (3, 7, or 14 mg) Off-label use of Ozempic for weight loss is common where insurance covers the diabetes indication but not the obesity one
Semaglutide hit one, tirzepatide two, retatrutide three
Activating MC1R, MC3R, and MC4R more broadly, producing tanning alongside significant pro-sexual, pro-erectile, and anorectic effects through central receptor activation
Medical strategies can help tackle weight plateaus